BioNxt Solutions Inc.
BNXT
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 190.70% | -99.32% | -97.53% | -46.07% | -86.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.70% | -99.32% | -97.53% | -46.07% | -86.52% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 190.70% | -99.32% | -97.53% | 118.09% | 101.24% |
| SG&A Expenses | 60.48% | -74.43% | 0.00% | -16.37% | -16.44% |
| Depreciation & Amortization | -53.19% | -59.17% | -53.01% | -13.90% | 46.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.06% | -67.56% | -8.69% | 1.72% | -37.40% |
| Operating Income | -20.16% | 64.74% | -2.83% | -2.62% | 36.16% |
| Income Before Tax | -2.67% | 59.43% | -5.51% | 68.69% | 28.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.67% | 59.43% | -5.51% | 66.58% | 28.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.67% | 59.43% | -5.51% | 66.58% | 28.32% |
| EBIT | -20.16% | 64.74% | -2.83% | -2.62% | 36.16% |
| EBITDA | -23.60% | 64.90% | -5.01% | -1.06% | 37.80% |
| EPS Basic | 10.38% | 63.48% | 9.32% | 71.04% | 40.11% |
| Normalized Basic EPS | 10.61% | 63.39% | 9.46% | 6.06% | 41.07% |
| EPS Diluted | 10.38% | 63.48% | 9.32% | 71.04% | 40.11% |
| Normalized Diluted EPS | 10.61% | 63.39% | 9.46% | 6.06% | 41.07% |
| Average Basic Shares Outstanding | 14.37% | 11.54% | 16.43% | 15.63% | 20.08% |
| Average Diluted Shares Outstanding | 14.37% | 11.54% | 16.43% | 15.63% | 20.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
